Amoéba: The €10 Million Capital Increase, Last Market Call Before 2029?
Through a press release published on October 19, 2026, Amoéba reiterated the terms of its capital increase with maintenance of preemptive subscription rights, with the subscription period remaining open until October 23, 2026. No new decisions are announced: the company reaffirmed the intended use of funds and the articulation of this transaction with the monetization of its cosmetic platform.
Biocontrol and Cosmetics, Two Destinations for Funds
According to the company based in Chassieu, this fundraising pursues two objectives: financing the commercial launch of the biocontrol activity and enabling Amoéba to prepare "under the best conditions" the monetization of its Willa cosmetic platform.
This monetization is then intended to take over to finance the company's development until financial autonomy is achieved, targeted from 2029 onwards. Subject to the realization of this monetization, the current transaction should constitute, according to Amoéba, the company's last market call until this horizon.
From a regulatory standpoint, the active substance obtained approval in the United States in 2022 and the positive and final opinion from EFSA in Europe. The Axpera product was approved in 2025 in the United States and in 2026 in France, ahead of other targeted European countries. The cosmetic ingredient is listed on the INCI list, which paves the way for its commercialization worldwide, with the exception of China where local approval is required.
Three Preemptive Rights for One New Share at €0.30, One Free Warrant Attached
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The capital increase, for an amount of approximately €10 million, is based on a ratio of 3 preemptive subscription rights for 1 new share at the price of €0.30. Each new share is accompanied by a warrant (BSA) allocated free of charge.
The transaction is open to all investors, and not exclusively to existing shareholders. It is eligible for PEA, PEA PME-ETI, the scheme under article 150-0 B ter of the French General Tax Code and the IR-SME tax reduction.
The company, listed on Euronext Growth, has also made available the recording of a webinar intended for individual investors as well as a letter addressed to individual shareholders.
Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
Expected revenue: 1,5 millions d'euros
Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
